Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis

Publisher： John Wiley & Sons Inc

E-ISSN： 1478-3231|35|1|90-100

ISSN： 1478-3223

Source： LIVER INTERNATIONAL (ELECTRONIC), Vol.35, Iss.1, 2015-01, pp. : 90-100

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 4, 2015-04 ,pp. : 366-375

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sofosbuvir with peginterferon‐ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

By  

HEPATOLOGY, Vol. 61, Iss. 3, 2015-03 ,pp. : 769-775

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy in Patients with Dose Reduction in Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis C

By  

Intervirology, Vol. 51, Iss. 1, 2008-02 ,pp. : 1-6

Karger

Access to resources Recommend Favorite

Prediction of Sustained Virologic Response Based on Week 4 and Week 12 Response in Hepatitis C Virus Genotype 1 Patients Treated with Peginterferon and Ribavirin: Assessment in a Favorable IL28B Allele-Prevalent Area

By  

Intervirology, Vol. 56, Iss. 3, 2013-01 ,pp. : 178-183

Karger

Access to resources Recommend Favorite

Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon‐based therapy: FUNDAMENTAL, a Phase II trial

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 7, 2015-07 ,pp. : 596-606

John Wiley & Sons Inc

Access to resources Recommend Favorite